| 101 |
11693468 | Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. | 2001 |
1 |
| 102 |
14728043 | Colesevelam. | 2001 |
1 |
| 103 |
10634817 | Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. | 2000 Jan |
1 |
| 104 |
10690940 | Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. | 2000 Feb |
1 |
| 105 |
10856769 | The role of small, dense low density lipoprotein (LDL): a new look. | 2000 Jun 30 |
1 |
| 106 |
10907971 | Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. | 2000 Jul |
1 |
| 107 |
11038166 | Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. | 2000 Nov |
2 |
| 108 |
11074211 | Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. | 2000 Nov 15 |
1 |
| 109 |
10500210 | 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. | 1999 Sep 28 |
1 |
| 110 |
9485553 | Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. | 1998 Feb |
1 |
| 111 |
9512650 | Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. | 1998 Jan 23 |
1 |
| 112 |
9551707 | Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. | 1998 Feb |
1 |
| 113 |
9793596 | Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. | 1998 Oct |
1 |
| 114 |
9821014 | Addressing the challenge. | 1998 Oct |
1 |
| 115 |
9856919 | Cost-effectiveness of statins. | 1998 Dec 1 |
1 |
| 116 |
9180240 | A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. | 1997 May |
1 |
| 117 |
9374129 | Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. | 1997 Oct |
1 |
| 118 |
9399600 | Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors. | 1997 Nov-Dec |
1 |
| 119 |
9549635 | Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. | 1997 Sep |
1 |
| 120 |
10225774 | The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia. | 1997 Feb |
1 |
| 121 |
10684465 | Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia. | 1997 Oct |
2 |
| 122 |
8690818 | Effect of age and gender on pharmacokinetics of atorvastatin in humans. | 1996 Mar |
1 |
| 123 |
8877677 | Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. | 1996 Aug |
2 |
| 124 |
8988072 | Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. | 1996 Dec |
1 |
| 125 |
7749881 | Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. | 1995 May |
1 |